Beta Bionics, Inc. (NASDAQ:BBNX) Stock Has Average Price Target of $24.00

Beta Bionics, Inc. (NASDAQ:BBNX) has been given a consensus recommendation of “Moderate Buy” by the fifteen analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $24.00.

Several research firms recently commented on BBNX. Weiss Ratings raised Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. Truist Financial lifted their price target on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. Barclays initiated coverage on Beta Bionics in a report on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 price target for the company. Bank of America upped their price objective on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Finally, UBS Group reiterated a “buy” rating and issued a $25.00 target price on shares of Beta Bionics in a research note on Tuesday, September 15th.

Insider Activity at Beta Bionics

In related news, insider Mike Mensinger sold 2,650 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total value of $58,300.00. Following the completion of the transaction, the insider owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. This represents a 1.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Russell sold 4,221 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the transaction, the insider directly owned 169,628 shares of the company’s stock, valued at approximately $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 98,472 shares of company stock valued at $1,920,481 in the last quarter. 5.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Beta Bionics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Beta Bionics during the 2nd quarter worth about $52,340,000. Eversept Partners LP lifted its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares in the last quarter. Bank of America Corp DE acquired a new stake in Beta Bionics in the 2nd quarter worth about $8,566,000. Perceptive Advisors LLC boosted its holdings in Beta Bionics by 39.8% in the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after buying an additional 240,000 shares during the last quarter. Finally, Bruce & Co. Inc. purchased a new stake in Beta Bionics during the 1st quarter worth approximately $5,518,000.

Beta Bionics Price Performance

BBNX opened at $19.16 on Friday. Beta Bionics has a 12-month low of $8.80 and a 12-month high of $32.71. The firm has a 50 day moving average of $19.13 and a two-hundred day moving average of $15.49.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, sell-side analysts predict that Beta Bionics will post -2.02 earnings per share for the current year.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Analysts reportedly have a consensus price target of $24.00, suggesting potential upside from recent trading levels if the company’s legal and regulatory issues are resolved. Beta Bionics consensus price target article
• Neutral Sentiment: Multiple law firms are publicizing a securities class action against Beta Bionics and the November 3, 2026 deadline for investors to seek lead-plaintiff status. The notices cover investors who purchased shares between July 30, 2025, and February 24, 2026. These announcements primarily provide procedural updates, but they reinforce the ongoing litigation risk. Beta Bionics investor deadline article
• Negative Sentiment: The lawsuit alleges that Beta Bionics and certain executives violated federal securities laws by minimizing the significance of an FDA Form 483 that cited more than 18,000 unreported iLet complaints. According to the legal notice, the shares fell from a class-period high of approximately $31.99 to below $9 across three disclosure events. The allegations are not proven, but the potential litigation, regulatory scrutiny, legal costs and reputational damage remain material risks for BBNX investors. Beta Bionics securities class action allegations article

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.